1 | Abatacept | Abatacept [36] Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (ctla4-ig); Abatacept (iv); Abatacept (sc); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept active treatment; Abatacept delayed-onset treatment; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Device: abatacept combination product (acp); Double-blind abatacept; Drug: abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Orencia® (abatacept); Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; | [1] D03203 D03203 💬 |
[2] CD80, CD86 💬 |
Allograft rejection [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |